1. Home
  2. ACOG vs APLT Comparison

ACOG vs APLT Comparison

Compare ACOG & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$6.23

Market Cap

115.5M

Sector

N/A

ML Signal

HOLD

Logo Applied Therapeutics Inc.

APLT

Applied Therapeutics Inc.

HOLD

Current Price

$0.11

Market Cap

18.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACOG
APLT
Founded
2000
2016
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
115.5M
18.0M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
ACOG
APLT
Price
$6.23
$0.11
Analyst Decision
Strong Buy
Hold
Analyst Count
1
3
Target Price
$18.00
$1.25
AVG Volume (30 Days)
102.3K
8.4M
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,427,199.00
$1,000,000.00
Revenue This Year
N/A
$124.18
Revenue Next Year
$132.35
$66.67
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.75
$0.10
52 Week High
$11.54
$1.50

Technical Indicators

Market Signals
Indicator
ACOG
APLT
Relative Strength Index (RSI) 55.48 26.01
Support Level $5.00 $0.10
Resistance Level $6.20 $0.13
Average True Range (ATR) 0.55 0.02
MACD 0.08 0.02
Stochastic Oscillator 72.00 7.91

Price Performance

Historical Comparison
ACOG
APLT

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

About APLT Applied Therapeutics Inc.

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Share on Social Networks: